Últimas noticias sobre Pro-Dex (NASDAQ:PDEX) Bolsa

Pro-Dex

Pro-Dex Inc is engaged in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used in the orthopedic, thoracic, and craniomaxillofacial (CMF) markets. The company also designs and manufactures multi-axis motion control systems used in factory automation and scientific research markets. Majority of the company's revenue is derived from designing, developing, and manufacturing surgical devices for the medical device and dental industries.

Pro-Dex Inc

Polkadex

WIIM

PDEX

Pro-Dex shares are trading higher after the company reported better-than-expected Q1 financial results.

Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) reported quarterly earnings of $0.75 per share which beat the analyst consensus estimate of $0.29 by 158.62 percent. The company reported quarterly sales of $14.892 million which beat the analyst consensus estimate of $12.100 million by 23.07 percent. This is a 24.74 percent increase over sales of $11.938 million the same period last year.

Earnings

Earnings Beats

News

Pro-Dex Q1 2025 GAAP EPS $0.75 Beats $0.29 Estimate, Sales $14.892M Beat $12.100M Estimate

<h3>Gainers</h3>
<ul>
<li>Athira Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHA#NASDAQ">ATHA</a>) stock rose 28.5% to $0.55 during Thursday's after-market session. The market value of their outstanding shares is at $21.0 million. </li>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) shares increased by 28.08% to $1.87. The company's market cap stands at $2.5 million. </li>
<li>Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) shares increased by 19.69% to $37.13. The market value of their outstanding shares is at $124.6 million. </li>
<li>ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) stock increased by 18.62% to $4.14. The market value of their outstanding shares is at $314.3 million. As per the news, the Q3 earnings report came out today. </li>
<li>Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) stock moved upwards by 7.7% to $54.49. The company's market cap stands at $6.9 billion. The company's, Q3 earnings came out today. </li>
<li>Ardelyx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>) shares rose 7.49% to $6.31. The company's market cap stands at $1.4 billion. The company's, Q3 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Biofrontera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) stock decreased by 10.6% to $1.1 during Thursday's after-market session. The company's market cap stands at $6.0 million. </li>
<li>BioRestorative Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) stock decreased by 5.74% to $1.47. The market value of their outstanding shares is at $10.1 million. </li>
<li>Palisade Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) stock decreased by 5.52% to $2.57. The company's market cap stands at $3.0 million. </li>
<li>Innovative Eyewear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) shares fell 5.49% to $7.75. The company's market cap stands at $18.6 million. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) shares fell 5.23% to $0.83. The company's market cap stands at $28.8 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) stock decreased by 5.12% to $1.67. The market value of their outstanding shares is at $15.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ARDX

ATHA

BFRI

BRTX

CDXC

HALO

LUCY

OCEA

PALI

TOVX

TRIB

12 Health Care Stocks Moving In Thursday's After-Market Session

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page.</a>
<ul>
<li>Ascendiant Capital raised the price target for Pro-Dex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) from $28 to $30. Ascendiant Capital analyst Edward Woo maintained a Buy rating. Pro-Dex shares gained 4.2% to close at $23.28 on Friday. <a href="https://www.benzinga.com/quote/PDEX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. boosted the price target for Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) from $16 to $30. HC Wainwright &amp; Co. analyst Mitchell Kapoor maintained a Buy rating. Summit Therapeutics shares fell 1.8% to close at $12.27 on Friday. <a href="https://www.benzinga.com/quote/MEI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan raised United States Steel Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) price target from $40 to $42. JP Morgan analyst Bill Peterson upgraded the stock from Neutral to Overweight. United States Steel shares gained 4.3% to close at $31.27 on Friday. <a href="https://www.benzinga.com/quote/SMMT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley raised Costco Wholesale Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) price target from $855 to $950. Morgan Stanley analyst Simeon Gutman maintained an Overweight rating. Costco shares fell 1.1% to close at $876.68 on Friday. <a href="https://www.benzinga.com/quote/COST/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wedbush boosted the price target for LGI Homes, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGIH#NASDAQ">LGIH</a>) from $97 to $125. Wedbush analyst Jay McCanless upgraded the stock from Underperform to Neutral. LGI Homes shares rose 0.8% to close at $104.80 on Friday. <a href="https://www.benzinga.com/quote/LGIH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>BTIG increased Roblox Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) price target from $47 to $51. BTIG analyst Clark Lampen maintained a Buy rating. Roblox shares fell 0.2% to close at $43.64 on Friday. <a href="https://www.benzinga.com/quote/RBLX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities raised JetBlue Airways Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) price target from $3 to $6. B of A Securities analyst Andrew Didora upgraded the stock from Underperform to Neutral. JetBlue shares fell 1.7% to close at $5.30 on Friday. S<a href="https://www.benzinga.com/quote/JBLU/analyst-ratings">ee how other analysts view this stock.</a></li>
<li>Deutsche Bank increased the price target for Colgate-Palmolive Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) from $107 to $109. Deutsche Bank analyst Steve Powers downgraded the stock from Buy to Hold. Colgate-Palmolive shares fell 0.6% to close at $107.86 on Friday. See how other analysts view this stock.</li>
<li>JP Morgan boosted Nucor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) price target from $170 to $174. JP Morgan analyst Bill Peterson upgraded the stock from Neutral to Overweight. Nucor shares fell 0.6% to close at $138.79 on Friday. <a href="https://www.benzinga.com/quote/NUE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>BMO Capital boosted Starbucks Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) price target from $100 to $110. BMO Capital analyst Andrew Strelzik maintained an Outperform rating. Starbucks shares fell 0.5% to close at $91.15 on Friday. <a href="https://www.benzinga.com/quote/SBUX/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying SBUX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="506" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09085953/image-70-1024x506.png" alt="" class="wp-image-537416" style="width:621px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09085953/image-70-1024x506.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09085953/image-70-300x148.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09085953/image-70-768x380.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09085953/image-70.png 1368w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>

Price Target

Pre-Market Outlook

Analyst Ratings

Trading Ideas

COST

JBLU

LGIH

RBLX

SBUX

SMMT

Starbucks To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Monday

Ascendiant Capital analyst Edward Woo maintains Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) with a Buy and raises the price target from $28 to $30.

Ascendiant Capital Maintains Buy on Pro-Dex, Raises Price Target to $30

Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) reported quarterly earnings of $0.46 per share which beat the analyst consensus estimate of $0.35 by 31.43 percent. This is a 9.52 percent increase over earnings of $0.42 per share from the same period last year. The company reported quarterly sales of $15.03 million which beat the analyst consensus estimate of $10.60 million by 41.75 percent. This is a 41.23 percent increase over sales of $10.64 million the same period last year.

Pro-Dex Q4 EPS $0.46 Beats $0.35 Estimate, Sales $15.03M Beat $10.60M Estimate

Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) reported quarterly earnings of $0.19 per share which missed the analyst consensus estimate of $0.35 by 45.71 percent. This is a 47.22 percent decrease over earnings of $0.36 per share from the same period last year. The company reported quarterly sales of $14.29 million which beat the analyst consensus estimate of $13.20 million by 8.28 percent. This is a 9.28 percent increase over sales of $13.08 million the same period last year.

Pro-Dex Q3 EPS $0.19 Misses $0.35 Estimate, Sales $14.29M Beat $13.20M Estimate

Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) reported quarterly earnings of $0.14 per share which missed the analyst consensus estimate of $0.35 by 60 percent. This is a 41.67 percent decrease over earnings of $0.24 per share from the same period last year. The company reported quarterly sales of $12.59 million which beat the analyst consensus estimate of $11.50 million by 9.46 percent. This is a 11.58 percent increase over sales of $11.28 million the same period last year.

Earnings Misses

Pro-Dex Q2 EPS $0.14, Sales $12.59M Beat $11.50M Estimate

<h3>Gainers</h3>
<ul>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) shares rose 10.5% to $0.66 during Thursday's after-market session. The market value of their outstanding shares is at $18.2 million. </li>
<li>Sensus Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRTS#NASDAQ">SRTS</a>) stock increased by 9.58% to $4.0. The company's market cap stands at $65.5 million. The company's, Q4 earnings came out today. </li>
<li>Corvus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) stock moved upwards by 8.49% to $2.17. The market value of their outstanding shares is at $106.4 million. </li>
<li>SenesTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNES#NASDAQ">SNES</a>) shares moved upwards by 6.86% to $1.09. </li>
<li>Coeptis Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COEP#NASDAQ">COEP</a>) stock rose 6.2% to $0.51. The company's market cap stands at $17.3 million. </li>
<li>Bright Green (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGXX#NASDAQ">BGXX</a>) shares moved upwards by 4.99% to $0.18. The company's market cap stands at $32.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>BioXcel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTAI#NASDAQ">BTAI</a>) stock fell 42.1% to $2.17 during Thursday's after-market session. The market value of their outstanding shares is at $64.9 million. </li>
<li>Renalytix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNLX#NASDAQ">RNLX</a>) stock declined by 29.76% to $0.38. The company's market cap stands at $19.0 million. </li>
<li>Syra Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRA#NASDAQ">SYRA</a>) stock fell 13.82% to $4.18. The company's market cap stands at $26.8 million. </li>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) stock fell 10.56% to $0.14. The market value of their outstanding shares is at $1.2 million. </li>
<li>NanoString Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSTG#NASDAQ">NSTG</a>) stock declined by 8.96% to $0.11. The market value of their outstanding shares is at $5.0 million. </li>
<li>Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) stock decreased by 8.28% to $19.5. The company's market cap stands at $69.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BGXX

BTAI

COEP

CRVS

NSTG

RNLX

SINT

SNES

SRTS

SYRA

Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $0.32 by 153.13 percent. This is a 158.62 percent decrease over earnings of $0.29 per share from the same period last year. The company reported quarterly sales of $11.94 million which beat the analyst consensus estimate of $11.20 million by 6.59 percent. This is a 7.68 percent increase over sales of $11.09 million the same period last year.

Pro-Dex Q1 EPS $(0.17) May Not Compare To $0.32 Estimate, Sales $11.94M Beat $11.20M Estimate

Pro-Dex shares are trading higher after the company reported better-than-expected Q4 EPS results.

Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) reported quarterly earnings of $0.42 per share which beat the analyst consensus estimate of $0.33 by 27.27 percent. This is a 10.53 percent increase over earnings of $0.38 per share from the same period last year.

Pro-Dex Q4 EPS $0.42 Beats $0.33 Estimate

Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate of $0.26 by 38.46 percent. This is a 200 percent increase over earnings of $0.12 per share from the same period last year. The company reported quarterly sales of $13.08 million which beat the analyst consensus estimate of $9.80 million by 33.46 percent. This is a 41.17 percent increase over sales of $9.27 million the same period last year.

Pro-Dex Q3 EPS $0.36 Beats $0.26 Estimate, Sales $13.08M Beat $9.80M Estimate

<a href="https://pro.benzinga.com/?utm_source=insights">According to Benzinga Pro data</a> Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) posted a 18.31% decrease in earnings from Q1. Sales, however, increased by 1.76% over the previous quarter to $11.28 million. Despite the increase in sales this quarter, the decrease in earnings may suggest Pro-Dex is not utilizing their capital as effectively as possible. In Q1, Pro-Dex earned $1.08 million and total sales reached $11.09 million. 
<h3>What Is Return On Capital Employed?</h3>
Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q2, Pro-Dex posted an ROCE of 0.04%.
It is important to keep in mind that ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but does not account for factors that could affect earnings and sales in the near future. 
ROCE is a powerful metric for comparing the effectiveness of capital allocation for similar companies. A relatively high ROCE shows Pro-Dex is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and, ultimately, earnings per share (EPS) growth. 
For Pro-Dex, the positive return on capital employed ratio of 0.04% suggests that management is allocating their capital effectively. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns.
<h3>Analyst Predictions</h3>
Pro-Dex reported Q2 earnings per share at $0.24/share, which did not meet analyst predictions of $0.29/share.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Pro-Dex's Return On Capital Employed Overview

Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) reported quarterly earnings of $0.24 per share which missed the analyst consensus estimate of $0.29 by 17.24 percent. This is a 4 percent decrease over earnings of $0.25 per share from the same period last year. The company reported quarterly sales of $11.28 million which beat the analyst consensus estimate of $10.40 million by 8.48 percent. This is a 10.90 percent increase over sales of $10.17 million the same period last year.

Pro-Dex Q2 EPS $0.24 Misses $0.29 Estimate, Sales $11.28M Beat $10.40M Estimate

<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data,</a> Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) posted Q1 earnings of $1.08 million, an increase from Q4 of 23.42%. Sales dropped to $11.09 million, a 12.11% decrease between quarters. In Q4, Pro-Dex earned $1.41 million, and total sales reached $12.62 million. 
<h3>Why Is ROIC Significant?</h3>
Return on Invested Capital is a measure of yearly pre-tax profit relative to capital invested by a business. Changes in earnings and sales indicate shifts in a company's ROIC. A higher ROIC is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROIC suggests the opposite. In Q1, Pro-Dex posted an ROIC of 2.52%.
Keep in mind, while ROIC is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future. 
ROIC is a powerful metric for comparing the effectiveness of capital allocation for similar companies. A relatively high ROIC shows Pro-Dex is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of invested capital, some of that money can be reinvested in more capital which will generally lead to higher returns and, ultimately, earnings per share (EPS) growth. 
For Pro-Dex, the positive return on invested capital ratio of 2.52% suggests that management is allocating their capital effectively. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns.
<h3>Analyst Predictions</h3>
Pro-Dex reported Q1 earnings per share at $0.29/share, which did not meet analyst predictions of $0.33/share.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Pro-Dex Earnings Perspective: Return On Invested Capital

Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) reported quarterly earnings of $0.29 per share. This is a 3.57 percent increase over earnings of $0.28 per share from the same period last year.

Pro-Dex Q1 EPS $0.29 Up From $0.28 YoY

Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) reported quarterly earnings of $0.38 per share. This is a 90 percent increase over earnings of $0.20 per share from the same period last year. The company reported $12.62 million in sales this quarter. This is a 33.70 percent increase over sales of $9.44 million the same period last year.

Pro-Dex Q4 EPS $0.38 Up From $0.20 YoY, Sales $12.62M Up From $9.44M YoY

Pro-Dex shares are trading lower after the company reported Q3 EPS and sales results were lower year over year.

Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) reported quarterly earnings of $0.12 per share. This is a 77.78 percent decrease over earnings of $0.54 per share from the same period last year. The company reported $9.30 million in sales this quarter. This is a 20.78 percent decrease over sales of $11.74 million the same period last year.

Pro-Dex Q3 EPS $0.12 Down From $0.54 YoY, Sales $9.30M Down From $11.74M YoY

Long Cast Advisers Q4 2023 Letter

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pro-Dex (NASDAQ:<a href="https://investorplace.com/stock-quotes/pdex-stock-quote/">PDEX</a>) just reported results for the third quarter of 2024.<ul><li>Pro-Dex reported earnings per share of 19 cents. This was below the analyst estimate for EPS of 35 cents.</li><li>The company reported revenue of $14.29 million.</li><li>This was 8.28% better than the analyst estimate for revenue of $13.20 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/pdex-stock-earnings-pro-dex-for-q3-of-2024/">PDEX Stock Earnings: Pro-Dex Misses EPS, Beats Revenue for Q3 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

PDEX Stock Earnings: Pro-Dex Misses EPS, Beats Revenue for Q3 2024

Pro-Dex GAAP EPS of $0.19 misses by $0.16, revenue of $14.3M beats by $1.1M

Micro-cap stocks carry high risk but can potentially deliver high returns. Given this backdrop, it could be wise to buy under-the-radar micro-cap stocks LifeVantage (LFVN), Pro-Dex (PDEX), and Lee Enterprises (LEE), which have high growth potential. Keep reading… Micro-cap stocks have the potential for rapid growth, particularly if they belong to high-growth industries or possess disruptive business models. This can lead to significant gains for investors who can identify and invest in promising micro-cap stocks.
Therefore, investors could consider buying fundamentally sound micro-cap stocks, LifeVantage Corporation (<a href="https://stocknews.com/stock/LFVN/">LFVN</a>), Pro-Dex, Inc. (<a href="https://stocknews.com/stock/PDEX/">PDEX</a>), and Lee Enterprises, Incorporated (<a href="https://stocknews.com/stock/LEE/">LEE</a>).
<a href="https://www.investopedia.com/terms/m/microcapstock.asp">Micro-cap stocks</a> have a market capitalization that lies approximately between $50 million and $300 million. These stocks emphasize long-term growth and operate with high efficiency, concentrating on expanding their businesses. Therefore, when chosen wisely, micro-caps can be highly beneficial for investors.
Moreover, micro-cap stocks can offer substantial returns, but high-quality ones often go unnoticed due to the limited media coverage they receive compared to large companies. Despite this, they have a history of outperformance. A <a href="https://www.boston-partners.com/uploads/2021/05/35500a7549a9e095691c5f66819b4d87/wpg-microcap-vs-pe-white-paper.pdf">Boston Partners report</a> shows that from early 1995 to June 2020, the CRSP Equal Weighted Microcap Index grew by 740%, surpassing the S&amp;P 500's 255% returns.
Considering these encouraging trends, let's take a look at the fundamentals of the three best micro-cap stocks.
LifeVantage Corporation (<a href="https://stocknews.com/stock/LFVN/">LFVN</a>)
LFVN engages in identifying, researching, developing, formulating, selling, and distributing nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care products, bath and body, and targeted relief products. It has a market cap of $80.20 million.
On May 2, 2024, the company paid its shareholders a quarterly dividend of $0.04 per share. The company pays an annual dividend of $0.16, which translates to a 2.47% yield with a four-year average yield of 2.51%.
In terms of forward non-GAAP P/E, LFVN is trading at 9.95x, 42.4% lower than the industry average of 17.29x. Likewise, the stock's forward EV/Sales and <a href="https://www.investopedia.com/terms/p/price-to-salesratio.asp">Price/Sales</a> multiples of 0.39 and 0.41 are 78% and 68.9% lower than their respective industry averages of 1.76 and 1.31.
In the third quarter, which ended March 31, 2023, LFVN reported revenue and gross profit of $48.25 million and $38.07 million, respectively. The company's non-GAAP net income and adjusted EPS amounted to $2.78 million and $0.21, up 169.9% and 162.5% year-over-year, respectively.
For the fiscal first quarter ending September 2024, LFVN's revenue is expected to amount to $49.63 million, while its EPS is forecasted to settle at $0.16. Further, its EPS and revenue are expected to rise 7.7% and 1.8% year-over-year to $0.70 and $205.84 million, respectively, in the fiscal year ending June 2025. Moreover, it topped the consensus EPS estimates in three of the trailing four quarters.
Over the past year, the stock has gained 44.5% to close the last trading session at $6.47.
LFVN's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect its robust outlook. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
LFVN has an A grade for Value, Sentiment, and Quality. The stock is ranked #2 out of 10 stocks within the A-rated <a href="https://stocknews.com/category/medical-consumer-goods/">Medical - Consumer Goods</a> industry.
To see the other ratings of LFVN for Growth, Momentum, and Stability, <a href="https://stocknews.com/stock/LFVN/">click here</a>.
Pro-Dex, Inc. (<a href="https://stocknews.com/stock/PDEX/">PDEX</a>)
By market cap, PDEX is valued at $65.13 million. It designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide.
In terms of forward EV/EBITDA, PDEX is trading at 8.35x, 39.1% lower than the industry average of 13.70x. Likewise, the stock's forward EV/Sales and Price/Sales multiples of 1.40 and 1.32 are 61.4% and 65.8% lower than their respective industry averages of 3.63 and 3.86.
In the third quarter that ended March 31, 2024, PDEX's net sales increased 3.9% year-over-year to $14.29 million, and its gross profit grew 5% year-over-year to $4 million. The company's net income and net income per share amounted to $ 655 thousand and $0.19, respectively.
Analysts expect PDEX's revenue for the quarter ending December 2024 to increase marginally year-over-year to $12.70 million. Its EPS for the same period is expected to increase 128.6% year-over-year to $0.32. Moreover, it topped the consensus revenue estimates in three of the trailing four quarters.
Shares of PDEX have surged 12.3% over the past nine months to close the last trading session at $19.05.
PDEX's sound fundamentals are reflected in its POWR Ratings. The stock has an overall rating of A, equating to a Strong Buy in our proprietary rating system.
PDEX has a B grade for Quality, Stability, Sentiment, and Value. It is ranked #3 out of 77 stocks in the A-rated <a href="https://stocknews.com/category/industrial-machinery/">Industrial - Machinery</a> industry.
In addition to the POWR Ratings highlighted above, you can check PDEX's ratings for Momentum and Growth <a href="https://stocknews.com/stock/PDEX/">here</a>.
Lee Enterprises, Incorporated (<a href="https://stocknews.com/stock/LEE/">LEE</a>)
Valued at $62.48 million by market cap, LEE provides local news and information, and advertising services in the United States. The company offers digital subscription platforms; daily, weekly, and monthly newspapers and niche publications; and web hosting and content management services.
LEE's forward EV/Sales and Price/Sales multiples of 0.86 and 0.10 are 55.4% and 92.1% lower than their respective industry averages of 1.93 and 1.25.
LEE's total operating revenue was reported at $146.55 million for the third quarter that ended March 24, 2024, and digital subscription revenue grew 44.8% year-over-year to $20.26 million. The company's adjusted EBITDA increased 5.2% from the year-ago value to $15.06 million.
Analysts expect LEE's EPS to grow 172% year-over-year to $0.68 for the quarter ended June 2024. Its revenue is expected to be $165.48 million. Also, the company has topped the consensus revenue estimates in three of the four trailing quarters, which is remarkable.
LEE's stock has gained 29.2% year-to-date to close the last trading session at $10.17.
LEE's POWR Ratings reflect its solid prospects. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system. 
LEE has a B grade for Growth, Sentiment, and Value. Within the A-rated <a href="https://stocknews.com/category/entertainment-publishing/">Entertainment - Publishing</a> industry, it is ranked first out of eight stocks.
To see LEE's additional ratings for Momentum, Stability, and Quality, <a href="https://stocknews.com/stock/LEE/">click here</a>.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>

<hr />
LFVN shares were trading at $6.58 per share on Tuesday afternoon, up $0.11 (+1.70%). Year-to-date, LFVN has gained 10.80%, versus a 17.43% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Nidhi Agarwal</h2> <img src='https:/wp-content/uploads/2023/03/Nidhi-Agarwal_Headshot-3.jpg' style="float:left; padding:5px;width:125px;">Nidhi is passionate about the capital market and wealth management, which led her to pursue a career as an investment analyst. She holds a bachelor's degree in finance and marketing and is pursuing the CFA program.

Her fundamental approach to analyzing stocks helps investors identify the best investment opportunities.<a href="https://stocknews.com/authors/?author=nidhi-agarwal">More...</a>The post <a href=https://stocknews.com/news/lfvn-pdex-lee-3-under-the-radar-micro-cap-stocks-to-buy/>3 Under-the-Radar Micro-Cap Stocks to Buy</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Under-the-Radar Micro-Cap Stocks to Buy

Pro-Dex (PDEX) has issued an announcement. Alisha K. Charlton, the CFO, and Richard L. Van Kirk, the CEO, received a substantial cash bonus for the...

Pro-Dex Executives Awarded Bonuses for Strong Fiscal Performance

Pro-Dex GAAP EPS of $0.46 beats by $0.11, revenue of $4.09M misses by $6.51M

Long Cast Advisers Q3 2024 Letter

Pro-Dex GAAP EPS of $0.75, revenue of $14.9M

Reports Q1 revenue $14.9M, one estimate $12.1M. Richard L. Van Kirk, the Company's President and CEO, commented, "We are pleased with our first qua...

Pro-Dex reports Q1 EPS 75c, one estimate 29c

Check out this evening's top movers from around Wall Street, compiled by The Fly. HIGHER AFTER EARNINGS – Pro-Dex (PDEX) up 45.1% Halozyme Therapeu...

Closing Bell Movers: Amazon gains 6%, Apple slips 2% on earnings

AAPL

ADMA

AMZN

BJRI

CCRD

ENVX

FOXF

INTC

LFVN

MAMA

MTRX

PESI

QRHC

RELL

RMAX

RSSS

SKYW

TEAM

TREE

Press Releases

Pro-Dex, Inc. Announces Fiscal 2024 First Quarter Results

Pro-Dex, Inc. Announces Fiscal 2024 Second Quarter and Six-Month Results

Pro-Dex, Inc. Announces Fiscal 2024 Third Quarter And Nine-Month Results

Pro-Dex, Inc. Announces Fiscal 2024 Fourth Quarter and Full-Year Results

PRO-DEX, INC. Announces Fiscal 2025 First Quarter Results

Accuray

Baird Medical Investment Holdings Ltd - Ordinary Share

Baird Medical Investment

HeartBeam

BrainsWay Ltd. - American Depositary Shares

BrainsWay

Alpha Tau Medical

electroCore

EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share

Comments

Pro-Dex

Noticias

Últimas noticias sobre Pro-Dex (NASDAQ:PDEX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL